ImmuPharma PLC (IMM)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

6.00p

Buy

6.20p

arrow-up0.00p (+0.00%)

Prices updated at 12 Dec 2025, 17:29 GMT

Prices minimum 15 mins delay

Prices in GBX

ImmuPharma PLC is a drug discovery and development company. The company along with its subsidiaries is engaged in the research and development of novel drugs based on peptide therapeutics to treat serious medical conditions including autoimmune diseases.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Timothy Paul McCarthy

CEO

Mr. Timothy Paul McCarthy

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

4

Head office

One Bartholomew Close

London

United Kingdom

EC1A 7BL

+44 2072062650

investors@immupharma.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Robert Reilly Laurence Non-Executive Director, Senior Independent	-
Ms. Lisa Baderoon Non-Executive Director, Head of Investor Relations	-
Dr. Sebastien R. Goudreau Executive Director, Chief Scientific Officer	-
Dr. Timothy Gary Franklin Executive Director, Chief Operating Officer	-
Mr. Timothy Paul McCarthy Executive Director, Chairman and Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Chelverton Asset Management Ltd	-

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.